Reviewed 10 November 2026 for medical education. This material is not a prescribing protocol; apply local clinical guidance and individual assessment.
Clinical objectives
Tocolysis temporarily delays preterm birth in appropriately selected patients, chiefly to permit antenatal corticosteroids, magnesium sulfate for fetal neuroprotection where indicated, and transfer to higher-level neonatal care. It does not reliably prevent prematurity long-term or itself improve every neonatal outcome [1,2].
Mechanisms and accepted drugs
- Nifedipine: a dihydropyridine L-type calcium-channel blocker that reduces myometrial calcium entry and contraction; among commonly used first-line options.
- Atosiban: competitive oxytocin-receptor antagonist used in some countries; availability differs.
- Indomethacin: cyclooxygenase inhibitor reducing prostaglandin synthesis, sometimes used briefly at earlier gestations under specialist assessment.
- Beta-2 agonists: terbutaline/ritodrine can relax myometrium but cause tachycardia and metabolic/cardiovascular toxicity; many guidelines advise against routine use.
Diltiazem and verapamil are not standard first-line tocolytics; the original ‘alphamine’ and ’emesicid’ listings were erroneous [1,2].
When to use or avoid
Gestational thresholds vary among national guidelines. NICE recommends nifedipine at 26+0 through 33+6 weeks for suspected or diagnosed preterm labour with intact membranes and permits consideration at 24+0 through 25+6 weeks. If nifedipine is unsuitable, an oxytocin-receptor antagonist is an alternative. Avoid unnecessary tocolysis when continuation of pregnancy is unsafe, such as severe infection, major bleeding or compelling fetal/maternal indication for delivery; preterm premature rupture of membranes requires separate assessment [2].
Maternal and fetal safety
Nifedipine can cause headache, flushing, hypotension and reflex tachycardia. Indomethacin may cause oligohydramnios and premature fetal ductus arteriosus constriction, with greater concern later in gestation; it is not a broadly safe late-pregnancy option. Beta-agonists can cause arrhythmia, hyperglycemia and pulmonary edema. Monitor hemodynamics, gestation-specific contraindications, fetal status and potential drug interactions [1,2].
Magnesium sulfate is not routine tocolysis
Magnesium sulfate is recommended in relevant preterm-birth scenarios for fetal neuroprotection, not as an effective primary tocolytic. It also treats/prevents seizures in preeclampsia/eclampsia when appropriate. Monitor reflexes, respirations, urine output and renal function to prevent toxicity [2].
Practical perspective
Tocolysis is short-term, specialist-directed obstetric care. Do not use long-term maintenance tocolysis routinely without evidence, and do not prescribe nonstandard agents from drug-class lists [1,2].
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- National Institute for Health and Care Excellence. Preterm labour and birth. NICE guideline NG25. Recommendations. Available from: https://www.nice.org.uk/guidance/ng25/chapter/Recommendations
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.